X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · IEX Real-Time Price · USD
0.759
+0.011 (1.47%)
At close: Jul 19, 2024, 4:00 PM
0.720
-0.039 (-5.14%)
Pre-market: Jul 22, 2024, 7:33 AM EDT

X4 Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2015
Revenue
000030
Upgrade
Gross Profit
000030
Upgrade
Selling, General & Admin
45.735.5127.0224.720.9417.64
Upgrade
Research & Development
69.8172.0261.0650.6541.9330.16
Upgrade
Other Operating Expenses
0.20-0.519.7603.9
Upgrade
Operating Expenses
115.71107.5287.5785.1162.8751.7
Upgrade
Operating Income
-115.71-107.52-87.57-85.11-59.87-51.7
Upgrade
Interest Expense / Income
6.545.783.993.642.692.15
Upgrade
Other Expense / Income
6.57-12.212.28-0.07-0.58-1.04
Upgrade
Pretax Income
-128.82-101.09-93.84-88.68-61.98-52.81
Upgrade
Income Tax
0.090.080.030.020.150
Upgrade
Net Income
-128.91-101.17-93.87-88.7-62.13-52.81
Upgrade
Preferred Dividends
002.5513.9400.59
Upgrade
Net Income Common
-128.91-101.17-96.41-102.64-62.13-53.4
Upgrade
Shares Outstanding (Basic)
20017864262012
Upgrade
Shares Outstanding (Diluted)
20017864262012
Upgrade
Shares Change
37.01%179.91%146.71%28.25%74.13%2411.98%
Upgrade
EPS (Basic)
-0.69-0.57-1.52-3.99-3.09-4.63
Upgrade
EPS (Diluted)
-0.69-0.57-1.52-3.99-3.09-4.63
Upgrade
Free Cash Flow
-103.71-96.57-77.21-71.52-60.18-48.23
Upgrade
Free Cash Flow Per Share
-0.52-0.54-1.22-2.78-3.00-4.18
Upgrade
Gross Margin
----100.00%-
Upgrade
Operating Margin
-----1995.80%-
Upgrade
Profit Margin
-----2071.03%-
Upgrade
Free Cash Flow Margin
-----2006.00%-
Upgrade
EBITDA
-120.35-93.32-87.85-83.15-58.07-49.99
Upgrade
EBITDA Margin
-----1935.50%-
Upgrade
Depreciation & Amortization
1.9321.991.891.230.67
Upgrade
EBIT
-122.28-95.31-89.85-85.04-59.3-50.66
Upgrade
EBIT Margin
-----1976.50%-
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).